Trial Profile
A Single Site, Randomized, Four-Way, Four-Period PK/PD Crossover Phase 1 Clinical Study in 16 Fasted Healthy Adult Volunteers Receiving 3 Dose Levels of Intranasally Administered Glucagon and One Dose Level of Glucagon Administered by Subcutaneous Injection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Glucagon (Primary) ; Glucagon
- Indications Hypoglycaemia
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 24 May 2016 New trial record